

# **Organizers**

Mercedes Robledo; José María de Campos; Jesús García-Donas, James Gnarra; Eric Jonasch, Mª Elena Kusak; Susi Martinez; Ilene Sussman; Karina Villar

#### **Scientific Committee**

José María de Campos; Carlos Cenjor; Graeme Eisenhofer; Eric Jonasch; Ma Elena Kusak; Eamonn Maher; Marcos Malumbres; Giuseppe Opocher; Mercedes Robledo; Karina Villar

October 22, 2014

19.00 p.m. Registration at the Hotel

October 23, 2014

**8.30** Registration (at the Symposium venue)

8.45 Welcome - Mercedes Robledo

9.00 Opening Lecture

Basic and clinical research in pheochromocytoma: a winning combination

**Karel Pacak** 

National Institutes of Health, Bethesda, USA



Session 1 New insight from OMIC approaches (talks: 20 minutes + 5 for discussion)

# 9.30 Metabolomic profiling

#### Othon Iliopoulos

Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, USA

9.55 Suppression of the Transcriptional Coactivator PGC-1 alpha Drives Metabolic Reprogramming and Tumor Growth in Renal Cell Carcinoma

#### **Amato Giaccia**

Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California, USA

## 10.20 Exomes/genomes

#### **Eamonn Maher**

Department of Medical Genetics. University of Cambridge, UK

## 10.45 Transcript-omics in VHL disease and renal cell carcinoma

# Rathmell WK

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA

#### 11.10 Coffee Break

# Session 2: The Cilia Centrosome cycle and VHL (talks: 20 minutes + 5 for discussion)

## 11.40 Role of VHL in Ciliogenesis

#### Wilhelm Krek

Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.

# 12.05 Aurora kinase and VHL in kidney cancer

## **Yannick Arlot**

Institut de Génétique et Developpement de Rennes, Rennes, France

# 12.30 – 13.15 Oral presentations (up to 3 short oral presentations)

# 13.30 Lunch and poster view

Session 3. *Diagnosis, prognostic markers and management of VHL* (talks: 20 minutes + 5 for discussion)

## 15.00 Diagnosis and Clinical management of VHL disease

## **Giuseppe Opocher**

Veneto Institute of Oncology, Padova, Italy

15.25 Molecular pathogenesis of a new syndrome of Pheo/Paraganglioma, somatostatinoma and Polycythemia with HIF2 alpha mutation

## **Zhengping Zhuang**

Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA.

## 15.50 Pathology of VHL disease

# **Alexander Vortmeyer**

Yale University School of Medicine, New Haven, USA.

#### 16.15 Coffee Break

#### 16.45 Screening and diagnostic aspects of Endolymphatic Sac Tumors ELSTs

#### Marie Louise Mølgaard Binderup.

Dept. of Cellular and Molecular Medicine, University of Copenhagen, Denmark.

# 17.10 Pregnancy and VHL

## **Jacques Lenders**

Radboud University Medical Center Nijmegen, The Netherlands.

# 17.35 Genetic counseling on VHL

#### Ignacio Blanco

Genetic Counselling Unit L'Hospitalet, ICO-Hospital Duran i Reynals, Barcelona, Spain.

# 18:00 Oral presentations (up to 3 short oral presentations)

18.50 - Bus to the Hotel

20.45 Dinner



# October 24, 2014

Session 4. Current therapeutic scenario: from the animal models to the patient (talks: 20 minutes + 5 for discussion)

9.00 State-of-the-art of the therapeutic approaches

# **Eric Jonasch**

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA

9.25 A zebrafish model to study and therapeutically manipulate hypoxia signaling in tumorigenesis

## **Rachel Giles**

University Medical Center Utrecht, The Netherland

9.50 Mouse models of cooperative tumour suppression in clear cell renal cell carcinoma

# Ian Frew

Institute of Physiology, University of Zurich, Zurich, Switzerland

#### 10.15 Coffee Break

10.45 Cutting edge advances in systemic treatments of neuroendocrine tumours

# Jaume Capdevila

Hospital Vall d'Hebron, Barcelona, Spain

11.10 Therapeutic markers of antiangiogenic drugs

#### Cristina Rodríguez-Antona

Hereditary Endocrine Cancer Group, CNIO, Madrid, Spain.

11.35 Therapeutic challenges in ocular involvement

## José García Arumi

Department of Ophthalmology, Hospital Valle de Hebrón, Barcelona Spain

12.00 – 12.45 Oral presentations (up to 3 short oral presentations)

13.00 Lunch and poster view



Session 5. Challenges in surgery of VHL patients (talks: 20 minutes + 5 for discussion)

14.30 Therapy for sporadic and von Hippel–Lindau related hemangioblastomas of the central nervous system

#### Sven Gläsker

Department of Neurosurgery, Freiburg University Medical Center, Freiburg, Germany.

14.55 Neurosurgery management of hemangioblastomas in difficult locations: Brain stem and spinal root hemangioblastomas - role por neuronavegation and intraoperative neurophysiological monitoring

## José María de Campos

Department of Neurosurgery, VHL Unit Care, Fundación Jiménez Díaz, Madrid Spain

15.25 Radiosurgery in CNS hemangioblastomas. When and how?

#### Ma Elena Kusak

Department of Neurosurgery, Radiosurgery Unit, Hospital Ruber Internacional Spain

15.50 Coffee Break

16.20 Minimally Invasive Surgery for Pheochromocytomas and Retroperitoneal Paragangliomas

#### Martin K. Walz

Kliniken Essen-Mitte, Klinik für Chirugie und Zentrum für Minimal Invasive Chirugie, Essen, Germany

16.45 Surgery for EndolymphaticSac Tumors (ELST) and auditory rehabilitation

## **Carlos Cenjor**

Fundación Jiménez Díaz, Madrid, Spain

17.10 Challenges in RCC surgery

# **Jean-Jacques Patard**

CHU, Bicêtre, France

17.35 – 18.20 Oral presentations (up to 3 short oral presentations)

18.40 - Bus to the Hotel

20.30 Speaker's dinner



# October 25, 2014

# VHL for families

8.30 - 9.00 a.m. Registration

9.00 The VHL disease explained to the families

#### **Karina Villar**

Health Department of Castile-La Mancha, Toledo Vice-president Alianza Española VHL, Spain.

9.30 The experience of the Spanish VHL Care Unit

# José María de Campos

Department of Neurosurgery, VHL Care Unit, Fundación Jiménez Díaz, Madrid, Spain.

10.00 Dealing with the Emotions of VHL Patient. Interactive activity with patients conducted by a psychologist

## Roberto Álvarez

Fundación Instituto San José. Hermanos de San Juan de Dios, Madrid, Spain.

11.00 **Break** 

12.00 VHLA's Cancer in Our Gene International Patient Databank

## **Ilene Sussman**

VHL Family Alliance, USA

12.30 Spanish VHL Alliance: Working together to find a cure

## **Susi Martínez**

Presidenta de la Alianza VHL, Spain.

13.00 Closure of the Symposium

## José María de Campos

Department of Neurosurgery, VHL Care Unit, Fundación Jiménez Díaz, Madrid, Spain.

14.30 Lunch